Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

BMC Infectious Diseases

David Strutton²  Raymond A Farkouh²  Giovanni Zanotti³  Cheryl L McDade¹  Stephanie R Earnshaw¹ 

[1] RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA;Pfizer Inc., 500 Arcola Road, Collegeville, PA, 19426, USA;Pfizer Canada Inc., 17300 Trans Canada, Kirkland, Quebec, H9J 2M5, Canada

关键词: Pneumococcal disease;    Pneumococcal conjugate vaccine;    Cost-effectiveness;    Vaccine;   

Others  :  1175390
DOI  :  10.1186/1471-2334-12-101

 received in 2011-10-11, accepted in 2012-04-24,  发布年份 2012

【 摘 要 】

Background

Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active immunization against Streptococcus pneumoniae causing invasive pneumococcal disease in infants and children. PCV13 offers broader protection against Streptococcus pneumoniae; however, PCV10 offers potential protection against non-typeable Haemophilus influenza (NTHi). We examined public health and economic impacts of a PCV10 and PCV13 pediatric national immunization programs (NIPs) in Canada.

Methods

A decision-analytic model was developed to examine the costs and outcomes associated with PCV10 and PCV13 pediatric NIPs. The model followed individuals over the remainder of their lifetime. Recent disease incidence, serotype coverage, population data, percent vaccinated, costs, and utilities were obtained from the published literature. Direct and indirect effects were derived from 7-valent pneumococcal vaccine. Additional direct effect of 4% was attributed to PCV10 for moderate to severe acute otitis media to account for potential NTHi benefit. Annual number of disease cases and costs (2010 Canadian dollars) were presented.

Results

In Canada, PCV13 was estimated to prevent more cases of disease (49,340 when considering both direct and indirect effects and 7,466 when considering direct effects only) than PCV10. This translated to population gains of 258 to 13,828 more quality-adjusted life-years when vaccinating with PCV13 versus PCV10. Annual direct medical costs (including the cost of vaccination) were estimated to be reduced by $5.7 million to $132.8 million when vaccinating with PCV13. Thus, PCV13 dominated PCV10, and sensitivity analyses showed PCV13 to always be dominant or cost-effective versus PCV10.

Conclusions

Considering the epidemiology of pneumococcal disease in Canada, PCV13 is shown to be a cost-saving immunization program because it provides substantial public health and economic benefits relative to PCV10.

【 授权许可】

   
2012 Earnshaw et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D: Progress in the prevention of pneumococcal infection. CMAJ 2005, 173(10):1149-1151.
• [2]Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW: Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49(2):205-212.
• [3]Kellner JD, Scheifele D, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ: Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J 2008, 27(6):526-532.
• [4]Tyrrell GJ, Lovgren M, Chui N, Minion J, Garg S, Kellner JD, Marrie TJ: Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006. Vaccine 2009, 27(27):3553-3560.
• [5]Bjornson G, Scheifele DW, Bettinger J, Patrick DM, Gustafson L, Daly P, Tyrrell GJ: Effectiveness of pneumococcal conjugate vaccine in Greater Vancouver, Canada: 2004–2005. Pediatr Infect Dis J 2007, 26(6):540-542.
• [6]Paulus S, David ST, Tang W, Winters M, Buxton J, Henry B, Patrick D: Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002–2005). Can Commun Dis Rep 2006, 32(14):157-161.
• [7]Degani N, Navarro C, Deeks SL, Lovgren M: Invasive bacterial diseases in northern Canada. Emerg Infect Dis 2008, 14(1):34-40.
• [8]Langley JM, Kellner JD, Solomon N, Robinson JL, Le Saux N, McDonald J, Ulloa-Gutierrez R, Tan B, Allen U, Dobson S, Joudrey H: Empyema associated with community-acquired pneumonia: a Pediatric Investigator’s Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis 2008, 8:129. BioMed Central Full Text
• [9]Synflorix Product Monograph. Pneumococcal conjugate vaccine (non-typeable Haemophilus influenzae [NTHi] protein D, diphtheria or tetanus toxoid conjugates) adsorbed. May 5, 2009.
• [10]Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(9512):740-748.
• [11]Prevnar*13 Product Monograph. Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein). Pfizer Canada, Inc, Kirkland, Quebec, Canada; November 16, 2010.
• [12][http:/ / www.medicines.org.uk/ EMC/ medicine/ 22743/ SPC/ Synflorix+suspension+for+injection+ in+pre-filled+syringe/ #FORM] webciteSynflorix Summary of Product Characteristics. Pneumococcal conjugate vaccine (non-typeable Haemophilus influenzae [NTHi] protein D, diphtheria or tetanus toxoid conjugates) adsorbed. GlaxoSmithKline Biologicals SA, Rixensart, Belgium; January 24, 2011. Accessed February 28, 2011
• [13]Talbird SE, Taylor TN, Knoll S, Fostad CR, Marti SG: Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2010, 28S:G23-G29.
• [14]Chuck AW, Jacobs P, Tyrrell G, Kellner JD: Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010, 28:5485-5490.
• [15]Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D: Cost-effectiveness of 10-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infection in Quebec. In Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA; September 12–15, 2010.
• [16]Comite sur L’Immunisation du Quebec: Evaluation of two new pneumococcal conjugate vaccines for pediatric immunization in Quebec. Institute National de Sante Publique du Quebec, Quebec; October 2010.
• [17]Statistics Canada: [http://www40.statcan.gc.ca/l01/cst01/demo10a-eng.htm] webciteCANSIM, table (for fee) 051–0001. Population by sex and age group. Canada; 2010a. Accessed February 28, 2011
• [18]Institut National de Sante Publique du Quebec: Programme de surveillance due pneumocoque: rapport 2009. Laboratoire de santé publique du Quebec, Quebec; September 2010.
• [19]Morrow A, De Wals P, Petit G, Guay M, Erickson LJ: The burden of pneumococcal disease in Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007, 18(2):121-127.
• [20]Petit G, De Wals P, Law B, Tam T, Erickson LJ, Guay M, Framarin A: Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003, 14(4):215-220.
• [21]Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkorsky A, Jackson LA: Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008, 26:4947-4954.
• [22]De Wals P, Carbon M, Sevin E, Deceuninck G, Ouakki M: Reduced physician claims of otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009, 28(9):e271-e274.
• [23]Giltner CL, Lovgren M, McGeer A, Hoang L, Horsman GB, Van Caseele P, Tyrrell GJ: Serotype distribution of Streptococcus pneumoniae in Canada from 1991 to 2009. Poster presented at 2011 PDF Research Day conference. University of Alberta, Edmonton, Alberta, Canada; May 11, 2011.
• [24]Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, Law B, Tyrrell G, for members of the Canadian Immunization Monitoring Program, Active (IMPACT): The effect of routine vaccination on invasive pneumococcal infection in Canadian children, immunization monitoring program, active 2000–2007. Vaccine 2010, 28:2130-2136.
• [25]Talbird SE, Ismaila AS, Taylor TN: A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine 2010, 28S:G3-G13.
• [26]Statistics Canada: [http://www12.statcan.gc.ca/health-sante/82-213/index.cfm?Lang=ENG] webciteHealth trends. 2010b. Statistics Canada catalogue no. 82-213-XWE. Accessed March 2, 2011
• [27]Scheifele D, Halperin S, Pelletier L, Talbot J, members of the Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPCAT): Invasive pneumococcal infections in Canadian children, 1991–1998: implications for new vaccination strategies. Clin Infect Dis 2000, 31:58-64.
• [28]Jette LP, Delage G, Ringuette L, Allard R, De Wals P, Lamothe F, Loo V, Pneumococcus Study Group: Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: Serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 2001, 733:737.
• [29]Kaye PA, Andrews NJ, Slack MPE, George RC, Miller E: The impact of pneumococcal conjugate vaccination in children in England and Wales four years after the introduction of PCV7. Den Haag, Netherlands; June 7–11, 2011. Abstract No. 713
• [30]Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Rodriguez M, Troitiño M, Rüttimann R, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L: Evaluating the efficacy of 10-valent pneumococcal non-typeable haemophilus influenza protein-D conjugate vaccine (PHid-CV) against community-acquired pneumonia in Latin America.. Den Haag, Netherlands; June 7–11 2011. Abstract No. 412
• [31]Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J: Residual economic burden of Streptococcus pneumonia- and nontypeable Haemophilus influenza-associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine 2010, 28S:G14-G22.
• [32]Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC: Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28(48):7634-7643.
• [33]Black S, Shinefield H, Baxter R, Austrian R, Elvin L, Hansen J, Lewis E, Fireman B: Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 2006, 24(suppl 2):S79-S80.
• [34]Deceuninck G, De Wals P, Boulianne N, De Serres G: Effectiveness of pneumococcal conjugate vaccine using a 2 + 1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010, 29(6):546-549.
• [35]Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L: Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PhiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28:S66-S76.
• [36]Goldblatt D: Establishing the correlate for pneumonia. Reykjavik, Iceland; June 11, 2008.
• [37]Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA, 004 Study Group: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(3):e493-e505. E-pub 2010 Aug 23
• [38]Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N: Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17(6):1017-1026. E-pub 2010 Apr 28
• [39]Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, for the PCV13 Infant Study Group: Safety and immunogenicity of a 13-Valent pneumococcal conjugate vaccine. Pediatrics 2010, 125:866.
• [40]Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB: Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first five years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:6.
• [41]Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815.
• [42]Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P: Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
• [43]van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Bruin JP, van Alphen L, Sanders EA: Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children. A randomized controlled trial. JAMA 2009, 302(2):159-167.
• [44]Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP: Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007, 161:1162-1168.
• [45]Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR: Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
• [46]Miller E, Andrews NJ, Waight PA, Slack MP, George RC: Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(10):760-768. Epub 2011 May 27
• [47]Koshy E, Murray J, Bottle A, Sharland M, Saxena S: Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. Thorax 2010, 65(9):770-774.
• [48]Cohen R, Levy C, Bingen E, Bonnet E, Koskas M, Attal S, Nave I, Fritzell B, Varon E: Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). Chicago, IL; September 17–20, 2011.
• [49]Moore M, Link-Gelles R, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, Scherzinger K, Juni B, Beall B, Whitney C: Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, 2010–11. March 13, 2012.
• [50]Prymula R, Kriz P, Kaliskova E, Pascal T, Poolman J, Schuerman L: Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009, 28(1):71-78.
• [51]Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, Lommel P, Kaliskova E, Pascal T, Borys D, Schuerman L: Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011, 29(10):1959-1967.
• [52]Statistics Canada[http://www40.statcan.ca/l01/cst01/econ46a-eng.htm] webcite 2011. CANSIM table (for fee) 326–0021 and catalogue nos. 62-001-X, 62-010-X, and 62-557-X. Consumer Price Index, historical summary (1991–2010). Accessed February 28, 2011
• [53]De Wals P, Petit G, Erickson LJ, Guay M, Tam T, Law B, Framarin A: Benefits and costs of immunization of children with pneumococcal vaccine in Canada. Vaccine 2003, 21:3757-3764.
• [54]Statistics Canada. Canadian Community Health Survey: [http://www.statcan.ca/english/concepts/health/cycle2_1/index.htm] webciteCycle 2.1. 2003. Accessed February 28, 2011
• [55]Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR: Reply to Strutton et al.: Response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2011. in press
• [56]Dagan R, Givon-Lavi N, Zamir O, Fraser D: Effect of a nonvalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003, 22(6):532-540.
• [57]Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinmand K, Pelton SI, Lipstich M, Hanage WP, Lee GM, Finkelstein JA: Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124(1):e1-e11.
• [58]Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C: Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 2011, 29(31):4963-4972. E-pub 2011 May 27
• [59]Morano R, Pérez F, Brosa M, Escolano IP: Cost-effectiveness analysis of pneumococcal vaccination in Spain. Gac Sanit 2011 Jun 1. in press
• [60]Strutton D, Hwang S, Farkouh R, Roberts C: Response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2011. in press
• [61]Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR: Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
• [62]Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R, Brown M, Gilbert L, Hogg G, Murphy D, Enhanced Invasive Pneumococcal Disease Surveillance Working Group Pneumococcal Working Party of the Communicable Diseases Network Australia: Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008, 32(1):18-30.
• [63]Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil Ad, Harrison C, Bayley K, Watson M, Richmond P: The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010 Jun 1, 50(11):1477-1486.
• [64]De Wals P, Carbon M, Fortin E, Pepin J, Douville-Fradet M: Vaccination of children with pneumococcal conjugate vaccine had no impact on hospital admissions for pneumonia in adults in Quebec. Boston, MA; September 12–15, 2010.
• [65]Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006, 25:779-781.